Page 102 - Read Online

Berghen et al. J Cancer Metastasis Treat 2021;7:58 https://dx.doi.org/10.20517/2394-4722.2021.123 Page 9 of 10

15. Siva S, Jackson P, Kron T, et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a
dose-response relationship. Radiother Oncol 2016;118:540-6. DOI PubMed
16. Devos G, Berghen C, Van Eecke H, et al. Oncological outcomes of metastasis-directed therapy in oligorecurrent prostate cancer
patients following radical prostatectomy. Cancers (Basel) 2020;12:2271. DOI PubMed PMC
17. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple
metastases from renal cell carcinoma. Cancer 2011;117:2873-82. DOI PubMed
18. Yang JC, Abad J, Sherry R. Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol 2006;16:131-5. DOI
PubMed
19. Tanis PJ, van der Gaag NA, Busch OR, van Gulik TM, Gouma DJ. Systematic review of pancreatic surgery for metastatic renal cell
carcinoma. Br J Surg 2009;96:579-92. DOI PubMed
20. Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol
2011;185:439-44. DOI PubMed PMC
21. Russo AE, Untch BR, Kris MG, et al. Adrenal metastasectomy in the presence and absence of extraadrenal metastatic disease. Ann
Surg 2019;270:373-7. DOI PubMed PMC
22. Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: Indications and technique of surgical intervention. J
Urol 2000;164:1505-8. PubMed
23. Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg
Am 2007;89:1794-801. DOI PubMed
24. Higuchi T, Yamamoto N, Hayashi K, et al. Long-term patient survival after the surgical treatment of bone and soft-tissue metastases
from renal cell carcinoma. Bone Joint J 2018;100-B:1241-8. DOI PubMed
25. Vickers MM, Al-Harbi H, Choueiri TK, et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain
metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin
Genitourin Cancer 2013;11:311-5. DOI PubMed
26. Stief C, Hagemann J, Kuczyk M, Jonas U. Surgery for metachronous solitary liver metastases of renal cell carcinoma. J Urol
1997;158:375-7. PubMed
27. Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol 2003;10:705-10.
DOI PubMed
28. Loh J, Davis ID, Martin JM, Siva S. Extracranial oligometastatic renal cell carcinoma: current management and future directions.
Future Oncol 2014;10:761-74. DOI PubMed
29. Franzese C, Franceschini D, Di Brina L, et al. Role of stereotactic body radiation therapy for the management of oligometastatic renal
cell carcinoma. J Urol 2019;201:70-6. DOI PubMed
30. Cochran DC, Chan MD, Aklilu M, et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell
carcinoma treated with Gamma Knife surgery. J Neurosurg 2012;116:978-83. DOI PubMed PMC
31. Stenman M, Sinclair G, Paavola P, Wersäll P, Harmenberg U, Lindskog M. Overall survival after stereotactic radiotherapy or surgical
metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiother Oncol
2018;127:501-6. DOI PubMed
32. Svedman C, Sandström P, Pisa P, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and
metastatic renal cell carcinoma. Acta Oncol 2006;45:870-5. DOI PubMed
33. Meyer E, Pasquier D, Bernadou G, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a
study of the Getug group. Eur J Cancer 2018;98:38-47. DOI PubMed
34. Marvaso G, Corrao G, Oneta O, et al. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Clin Transl Oncol 2021;23:1717-26. DOI PubMed
35. Kano H, Iyer A, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Outcome predictors of gamma knife radiosurgery for renal
cell carcinoma metastases. Neurosurgery 2011;69:1232-9. DOI PubMed
36. Singh R, Ansinelli H, Sharma D, et al. Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: a multi-
institutional experience. J Radiosurg SBRT 2020;7:29-37. PubMed PMC
37. Ranck MC, Golden DW, Corbin KS, et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am
J Clin Oncol 2013;36:589-95. DOI PubMed
38. Wersäll PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother
Oncol 2005;77:88-95. DOI PubMed
39. Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided
intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2012;82:1744-8.
DOI PubMed PMC
40. Ikushima H, Tokuuye K, Sumi M, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J
Radiat Oncol Biol Phys 2000;48:1389-93. DOI PubMed
41. Gundem G, Van Loo P, Kremeyer B, et al; ICGC Prostate Group. The evolutionary history of lethal metastatic prostate cancer. Nature
2015;520:353-7. DOI PubMed PMC
42. Berghen C, Joniau S, Vulsteke C, et al. Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news.
Ecancermedicalscience 2020;14:1036. DOI PubMed PMC
43. Mohamad O, Sishc BJ, Saha J, et al. Carbon ion radiotherapy: a review of clinical experiences and preclinical research, with an
emphasis on DNA damage/repair. Cancers (Basel) 2017;9:66. DOI PubMed PMC